Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice

Journal of Infectious Diseases

Volumn 199, Issue 11, 2009, Pages 1629-1637

  Takahashi, Yoshimasa ^a,b   Hasegawa, Hideki ^a   Hara, Yukari ^a   Ato, Manabu ^a   Ninomiya, Ai ^a   Takagi, Hirotaka ^a   Odagiri, Takato ^a   Sata, Tetsutaro ^a   Tashiro, Masato ^a   Kobayashi, Kazuo ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTISERUM; HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE; VIRUS SIALIDASE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOADSORPTION; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; VIRUS ATTACHMENT; VIRUS GENE; VIRUS IMMUNITY; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; FLOW CYTOMETRY; HEMAGGLUTINATION, VIRAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED;

EID: 67650679858     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/598954     Document Type: Article

References (21)

1. Horimoto T, Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol Med 2006; 12:506-14.
2. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
3. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64.
4. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-7.
5. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9.
6. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197:667-75.
7. Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 2005; 102:12915-20.
8. Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007;25:3554-60.
9. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37:529-49.
10. Lu X, Edwards LE, Desheva JA, et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006; 24:6588-93.
11. Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989;63:1239-46.
12. Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA 1987; 84:6869-73.
13. Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 1968;2:281-8.
14. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008; 26:2350-9.
15. ++ on the stability of influenza virus neuraminidase. Arch Virol 1976; 52:7-18.
16. Feng JQ, Mozdzanowska K, Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavychain isotype. J Virol 2002; 76:1369-78.
17. Lu BL, Webster RG, Hinshaw VS. Failure to detect hemagglutinationinhibiting antibodies with intact avian influenza virions. Infect Immun 1982; 38:530-5.
18. Kaverin NV, Rudneva IA, Govorkova EA, et al. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 2007; 81:12911-7.
19. Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006; 352:418-26.
20. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007;4:265-71.
21. Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008; 3:1-14.